Metro International Biotech is a privately-owned clinical-stage pharmaceutical company that has established the most comprehensive portfolio of proprietary NAD+ precursors in the world.

NAD+ levels have been shown to decline as humans age and increasing NAD+ to preserve health and normal metabolism is believed to have broad pharmaceutical potential. Metro International Biotech has assembled a team of industry-leading scientists to drive its lead compound, MIB-626, through clinical development and fuel the Company’s robust R&D engine, building a library of next-generation analogs with tissue-selective NAD+ increasing properties.